Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
When combined with cytology, UroSEEK detected 95% of patients who developed bladder cancer
Use of 5-alpha-reductase inhibitors before and after diagnosis of the malignancy is associated with a 15% and 22% decreased risk of bladder cancer mortality, respectively.
In multivariable analyses, CKD stage G3b or higher was significantly associated with worse progression-free and cancer-specific survival.
Model, based on 6 factors, predicts overall survival for patients treated with atezolizumab
Appears to be a cost-effective strategy for patients with small size, stage pTa or pT1a recurrent tumors
In a 3-year study, toxic effects of atezolizumab remained manageable and responses durable.
Study results serve as a caution against relying on ureteroscopic biopsy to establish tumor grade and stage, researchers say.
Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
Nicotine and nicotine-derived nitrosamine ketone enhance mutational susceptibility in human cells.
A Charlson Comorbidity Index score of 2 or higher is an independent risk factor for urinary tract infections within 90 days following radical cystectomy for bladder cancer, study finds.
Diffusion-weighted imaging and use of higher field strengths further improve accuracy.
The locoregional recurrence-free survival rate at 2 years was significantly higher for patients treated with chemotherapy plus RT versus those treated with chemotherapy alone.
Patients on hemodialysis who undergo radical cystectomy for bladder cancer have 30-day and 5-year mortality rates of 9.3% and 87.9%, respectively, study finds.
Patients with versus without a history of urinary calculi had nearly 2-fold greater odds of bladder cancer, meta-analysis showed.
40% of active surveillance events were deemed to require treatment.
Chemoradiation for muscle-invasive bladder cancer is associated with a lower 1-year mortality risk versus radical cystectomy, but at year 2 and beyond, mortality risk is lower with radical cystectomy.
No evidence that varenicline, bupropion, or nicotine replacement increase probability of abstinence.
Durable survival, response rates rarely recognized as significant by current oncology value frameworks.
Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.
The proportion of patients who received neoadjuvant chemotherapy for muscle-invasive bladder cancer prior to cystectomy rose from 4% to 27% of patients from 1994 to 2013.
A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.
About 45.1% of cancer deaths and 42% of all incident cancers are linked to modifiable risk factors.
Mean disease-specific survival at 10 years was 50.9% for TMT and 57.8% for RC patients, a non-significant difference.
Reduction occurred after implementation of EPA's maximum contaminant level for arsenic
General practitioners less likely to support smoking cessation in patients with cancer than with CHD
FDA has accepted a supplemental New Drug Application asking to expand the labeling indication for Cysview to include use the bladder cancer-detecting system in the outpatient setting.
Tool incorporates the relative contribution of tumor stage, lymph node involvement.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)